Lilly to sell hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals
Eli Lilly and Company (Lilly) has agreed to sell its severe hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals in a deal potentially worth up to $1.07 ... Read More
Mylan, Biocon get FDA approval for Semglee in type 1 and 2 diabetes
Mylan and Biocon have secured approval from the US Food and Drug Administration (FDA) for Semglee (insulin glargine injection) in vial and pre-filled pen presentations ... Read More
Smokers with Diabetes have high risk of early death!
As per the recent study by Kavita Garg, an Indian-origin researcher at the University of Colorado-Denver in US, diabetic persons with heavy smoking habit have ... Read More